TITLE

Gene in some melanomas linked to worse outcomes

PUB. DATE
March 2013
SOURCE
British Journal of Hospital Medicine (17508460);Mar2013, Vol. 74 Issue 3, p128
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the identification of the TP63 gene, present in some melanomas, which is responsible for making tumor cells difficult to treat and leads to a worse clinical outcome.
ACCESSION #
86431977

 

Related Articles

  • Linking SOX10 to a slow-growth resistance phenotype. Zhang, Gao; Herlyn, Meenhard // Cell Research;Aug2014, Vol. 24 Issue 8, p906 

    Slow-cycling BRAF melanoma cells are notoriously resistant to standard chemotherapy or targeted therapy but the underlying mechanism remains elusive. Now a new study unlocks this mystery and offers novel insights into developing more effective therapeutic interventions.

  • Gene expression profiling explains melanoma subset. Hannapel, Coriene E. // Dermatology Times;Nov2000, Vol. 21 Issue 11, p30 

    Reports on the use of gene expression profiling to uncover a molecular signature, or set of differences, for a subset of melanomas. Differences in melanoma patients' response to therapy; Highlights of the study completed by an international team of scientists and directed by researchers from...

  • PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Massi, D.; Brusa, D.; Merelli, B.; Ciano, M.; Audrito, V.; Serra, S.; Buonincontri, R.; Baroni, G.; Nassini, R.; Minocci, D.; Cattaneo, L.; Tamborini, E.; Carobbio, A.; Rulli, E.; Deaglio, S.; Mandalà, M. // Annals of Oncology;Dec2014, Vol. 25 Issue 12, p2433 

    PD-L1 expression was an independent negative prognostic marker in human metastatic melanoma tissues and PD-L1+ melanoma cell lines showed a highly invasive phenotype and enhanced ability to grow in xenograft models. Our data suggest that PD-L1+ melanomas should be considered a disease subset...

  • Proteasomal Degradation of Mcl-1 by Maritoclax Induces Apoptosis and Enhances the Efficacy of ABT-737 in Melanoma Cells. Pandey, Manoj K.; Gowda, Krishne; Doi, Kenichiro; Sharma, Arun K.; Wang, Hong-Gang; Amin, Shantu // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background and purpose: Metastatic melanoma remains one of the most invasive and highly drug resistant cancers. The over expression of anti-apoptotic protein Mcl-1 has been associated with inferior survival, poor prognosis and chemoresistance of malignant melanoma. A BH3 mimetic, ABT-737, has...

  • A gene expression signature identifying transient DNMT1 depletion as a causal factor of cancer-germline gene activation in melanoma. Cannuyer, Julie; Van Tongelen, Aurélie; Loriot, Axelle; De Smet, Charles // Clinical Epigenetics;10/26/2015, Vol. 7, p1 

    Background: Many human tumors show aberrant activation of a group of germline-specific genes, termed cancergermline (CG) genes, several of which appear to exert oncogenic functions. Although activation of CG genes in tumors has been linked to promoter DNA demethylation, the mechanisms underlying...

  • Expression of the Tumor Suppressor Gene Product p16[sup INK4] in Benign and Malignant ... Keller‐Melchior, Regine; Schmidt, Rodney; Piepkorn, Michael // Journal of Investigative Dermatology;Jun98, Vol. 110 Issue 6, p932 

    The gene MTS1 encodes p16INK4, an inhibitor of cyclin‐dependent kinase 4, and is frequently deleted, mutated, or silenced by promoter methylation in melanoma cells and in the germline of familial melanoma patients. Although MTS1 may thus be the candidate melanoma suppressor gene that maps...

  • Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. Wang, Jinhua; Huang, Sharon K; Marzese, Diego M; Hsu, Sandy C; Kawas, Neal P; Chong, Kelly K; Long, Georgina V; Menzies, Alexander M; Scolyer, Richard A; Izraely, Sivan; Sagi-Assif, Orit; Witz, Isaac P; Hoon, Dave S B // Journal of Investigative Dermatology;Feb2015, Vol. 135 Issue 2, p532 

    BRAF mutations are frequent in cutaneous melanomas, and BRAF inhibitors (BRAFi) have shown remarkable clinical efficacy in BRAF mutant melanoma patients. However, acquired drug resistance can occur rapidly and tumor(s) often progresses thereafter. Various mechanisms of BRAFi resistance have...

  • Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. Wheler, Jennifer; Yelensky, Roman; Falchook, Gerald; Kim, Kevin B.; Hwu, Patrick; Tsimberidou, Apostolia M.; Stephens, Philip J.; Hong, David; Cronin, Maureen T.; Kurzrock, Razelle // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance. Methods: Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or...

  • Protein Tyrosine Phosphatase Genes Downregulated in Melanoma. McArdle, Linda; Rafferty, Mairin; Mælandsmo, Gunhild M; Bergin, Orla; Farr, Christine J; Dervan, Peter A; O'Loughlin, Sean; Herlyn, Meenhard; Easty, David J // Journal of Investigative Dermatology;Nov2001, Vol. 117 Issue 5, p1255 

    Phospho-tyrosine levels are increased in melanoma, apparently consistent with reports of elevated protein tyrosine kinase activity. Some protein tyrosine kinases are encoded by oncogenes and have been implicated in melanoma genesis. Decreased protein tyrosine phosphatase activity may also...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics